RxDoctor Payments Data

Darlene Espinosa, MD

Family Medicine · Upland, CANPI 1619105541

Payments from drug & device makers

$1,464in general payments, 2019–2025

Across 82 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$210
  • AbbVie$174
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$109
  • Johnson & Johnson$108
  • Novo Nordisk$83
  • Abbott$78
  • plus $702 from 27 others

What the payments were for

  • Food & beverage$1,464100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,464 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$50,886
Medicare patients
166
Services billed
484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$49,054
EliquisApixaban39$45,437
JardianceEmpagliflozin42$42,253
TrulicityDulaglutide29$34,548
JanuviaSitagliptin Phosphate28$26,466
XareltoRivaroxaban27$25,112
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$23,126
MyrbetriqMirabegron24$21,563
LinzessLinaclotide18$14,866
Wixela InhubFluticasone Propion/Salmeterol16$4,212
SynthroidLevothyroxine Sodium65$4,156
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$3,856
Gabapentin166$3,316
Levothyroxine Sodium268$2,958
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen121$2,658

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$83$49,05442 claims
PfizerEliquis$53$45,43739 claims
Boehringer IngelheimJardiance$36$42,25342 claims
Lilly USA, LLCTrulicity$15$34,54829 claims
MerckJanuvia$45$26,46628 claims
Johnson & JohnsonXarelto$108$25,11227 claims
GSKTrelegy Ellipta$50$23,12616 claims
Astellas Pharma US IncMyrbetriq$32$21,56324 claims
AbbVieLinzess, Synthroid$174$19,02283 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Upland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →